Trial Profile
An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg Imatinib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Sep 2023
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms DASCERN
- Sponsors Bristol-Myers Squibb
- 13 Dec 2022 Results(data cutoff, April 24, 2022; n=260; 5-Year Results) assessing safety and efficacy of Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib in Patients with Chronic Myeloid Leukemia safety presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 19 May 2022 This trial has been completed in Poland (end date: 12 Apr 2022), according to European Clinical Trials Database record.
- 14 May 2022 This trial has been completed in Czechia (end date: 12 Apr 2022), according to European Clinical Trials Database record.